Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean
The deal gives 14 countries a new purchasing route for the twice-yearly HIV prevention drug as new infections rose 13% from 2010 to 2024, Gilead said.
- On Tuesday, Gilead Sciences reached an agreement with the Pan American Health Organization to expand access to its HIV prevention drug Yeztugo across Latin America and the Caribbean.
- New HIV infections in Latin America and the Caribbean rose 13% between 2010 and 2024, prompting Gilead to address gaps in the utilization of prevention medicines.
- The agreement creates a new procurement pathway through PAHO for 14 countries including Brazil, Mexico, and Argentina, which were not covered by Gilead's voluntary generic licensing deals.
- PAHO Director Jarbas Barbosa said the initiative gives countries another HIV prevention option, while Gilead discusses possible local production of Yeztugo with Brazil's Health Ministry.
- Gilead has forecast $1 billion in sales for the drug in 2026, though actual availability depends on country-specific regulatory approvals and decisions by individual governments.
21 Articles
21 Articles
Los Angeles (USA), 15 Sep (EFE).- The pharmaceutical company Gilead Sciences announced on Tuesday an agreement with the Pan American Health Organization (PAHO) to accelerate access to lenacapavir, a six-monthly administration drug for HIV prevention through pre-exposure prophylaxis (PREP), in all PAHO member States in Latin America and the Caribbean. The pact, articulated through the PAHO Regional Revolving Funds, creates a coordinated regional …
cedarnews.net
EBCThe Pan-American Health Organization (Opas) will expand access to lenacapavir medicine for the prevention of HIV in Latin America and the Caribbean. The Pan-American Health Organization (Opas) will expand access to lenacapavir medicine for the prevention of HIV in Latin America and the Caribbean. The Pan-American Health Organization (OPas) will expand access to lenacapavir medicine for the prevention of HIV in Latin America and the Caribbean. Th…
Drug, called Sunlenca commercially, is an injectable drug only applied twice a year. AP via Business Wire The Pan-American Health Organization (PAHO) will expand access to lenacapavir for HIV prevention in Latin America and the Caribbean. 我Lenacapavir is an injectable drug that works as an additional option for pre-exposure HIV (PrEP) prophylaxis, an effective and long-term alternative to oral pills. Through a new agreement with Gilead Sciences,…
WASHINGTON – The Pan American Health Organization (PAHO) announced a new access route to Lenacapavir for HIV prevention in Latin America and the Caribbean, through an agreement with the US biopharmaceutical company Gilead Sciences. The initiative will allow 14 countries in the region to access this long-acting drug for [...]
The Pan American Health Organization (OPAS) will expand access to lenacapavir medicine for HIV prevention in Latin America and the Caribbean. Antiretroviral will be made available to a total of 14 countries in the region – including Brazil. The entity's data indicate about 140,000 new HIV infections registered every [...]
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
